AstraZeneca PLC (ETR:ZEG)
120.45
-0.95 (-0.78%)
Jul 16, 2025, 5:35 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.69
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
187.73B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
AstraZeneca News
- 1 day ago - Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug - Business Upturn
- 1 day ago - Boost for AstraZeneca after successful trial of experimental blood pressure drug - This is Money
- 2 days ago - AstraZeneca's baxdrostat meets key goals in late-stage trial for hypertension - Seeking Alpha
- 2 days ago - AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial - Benzinga
- 2 days ago - AstraZeneca shares show signs of life after successful trials of hypertension drug - MarketWatch
- 2 days ago - Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension - Business Wire
- 2 days ago - AstraZeneca drug lowers high BP in late-stage study; shares rise - Reuters
- 4 days ago - Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga